Grifols stands as a venerable force in the global healthcare sector, with a history dating back to 1940. Originating from the collaborative vision of hematologist Josep Antoni Grífols i Roig and his sons in post-war Barcelona, the company has transformed from a family-run lab into a powerhouse in Biotechnology, Health Care, and Manufacturing.
Renowned for pioneering innovations, Grifols made significant strides in medical sciences, notably in plasmapheresis technology since 1951. Their slogan, "Develops, produces and provides innovative healthcare services and solutions in more than 110 countries", encapsulates their expansive reach and commitment to medical advancements.
Recently, Grifols secured a substantial €1.30 billion post-IPO debt investment in late 2024, a testament to sustained investor confidence. This sizable influx of capital signals a robust growth trajectory, enticing potential investors looking for stability in a longstanding market leader with a footprint in over 110 countries.
